安徽山河药用辅料股份有限公司 独立董事 2024 年度述职报告 述职人：王宏 （一）出席董事会及专门委员会和股东大会的情况 本人本着勤勉尽责的态度，参加公司召开的董事会并列席公司股东大会。 自任职日 2024 年 8 月 1 日至 2024 年 12 月 31 日，公司共召开董事会 3 次，本人亲自出席董事会会议 3 次，没有连续两次未亲自出席会议的情况。在 一、独立董事基本情况 王宏女士：现任公司独立董事。本科学历，中国注册会计师、中国注册资产 评估师、注册土地估价师。历任安徽省国防工业办公室皖东机械厂财务科会计， 安徽中华会计师事务所执业助理，安徽省资产评估事务所部门经理，安徽皖资会 计师事务所所长，曾赴美国参加注册会计师行业交流、培训。现任芜湖长信科技 股份有限公司（股票代码 300088）独立董事。 作为独立董事，本人未在公司担任除独立董事以外的其他任何职务，没有为 公司提供财务、法律、管理咨询、技术咨询等服务，其配偶、父母、子女、主要 社会关系也未在公司任职，也未在公司主要股东公司担任任何职务，没有从公司 及其主要股东或有利害关系的机构和人员取得额外的未予披露的其他利益，不存 在影响独立性的情况。 ...

安徽山河药用辅料股份有限公司 独立董事 2024 年度述职报告 周建平先生：现任公司独立董事。1978-1982 年获中国药科大学（原南京药 学院）药学学士学位，1982~1985 年在中国兽药监察所工作，1985~88 年获中国 药科大学药剂学硕士学位后留校，从事药剂学科研、教学工作至今。其中 1991~1992 年在日本近畿大学药学部访问学者；2001 年获中国药科大学药剂学博 士学位。现任中国药科大学药剂系教授（二级）、博士生导师；国家药典委员会 执行委员（药剂专业主任委员），江苏省药学会和南京药学会药剂专业主任委员、 常务理事；苏州韬略生物科技股份有限公司、江苏德源药业股份有限公司、江苏 万高药业股份有限公司独立董事。 作为独立董事，本人未在公司担任除独立董事以外的其他任何职务，没有为 公司提供财务、法律、管理咨询、技术咨询等服务，其配偶、父母、子女、主要 社会关系也未在公司任职，也未在公司主要股东公司担任任何职务，没有从公司 及其主要股东或有利害关系的机构和人员取得额外的未予披露的其他利益，不存 在影响独立性的情况。 二、独立董事年度履职情况 （一）出席董事会及专门委员会和股东大会的情况 本人本着勤 ...

安徽山河药用辅料股份有限公司 独立董事 2024 年度述职报告 述职人：顾光（已离职） 本人顾光在 2024 年度担任安徽山河药用辅料股份有限公司（以下简称"公 司"）的独立董事，根据《公司法》、《证券法》、《上市公司独立董事管理办 法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范 运作》及《公司章程》的规定和要求，忠实履行了独立董事的职责，谨慎、认真、 勤勉地行使了独立董事的权利，积极出席相关会议，认真审议董事会各项议案， 对公司相关事项发表同意意见。因公司第五届董事会任期届满，本人自 2024 年 8 月起不再担任公司独立董事、审计委员会主任委员、薪酬与考核委员会委员， 现就本人 2024 年度履职情况汇报如下： 一、独立董事基本情况 顾光女士：管理学硕士，中国注册会计师(非执业会员)。历任安徽大学财务 管理系主任、会计学系主任、会计专硕中心主任。安徽大学商学院副教授、硕士 生导师，现已退休。现任芜湖埃泰克汽车电子股份有限公司、阳光电源股份有限 公司独立董事。 作为独立董事，本人未在公司担任除独立董事以外的其他任何职务，没有为 公司提供财务、法律、管理咨询、技术咨询等服务，其配偶 ...

Financial Performance - The company's revenue for Q1 2025 was ¥247,871,756.30, representing a 4.28% increase compared to ¥237,688,540.94 in the same period last year[4] - Net profit attributable to shareholders decreased by 5.30% to ¥47,176,895.69 from ¥49,815,076.00 year-on-year[4] - The company's basic earnings per share decreased by 4.76% to ¥0.20 from ¥0.21 in the same period last year[4] - Net profit for the current period was ¥46,658,366.21, a decrease of 7.4% from ¥50,518,085.80 in the previous period[22] - Earnings per share (EPS) for the current period was ¥0.20, down from ¥0.21 in the previous period[23] Cash Flow - The net cash flow from operating activities improved by 37.36%, reaching -¥6,407,841.51 compared to -¥10,229,557.31 in the previous year[4] - Operating cash inflow totaled $191,178,322.84, an increase of 6.8% from $179,860,893.79 in the previous period[24] - Net cash outflow from operating activities was -$6,407,841.51, improving from -$10,229,557.31 in the prior period[24] - Investment cash inflow reached $207,987,163.69, up from $123,826,360.05, marking a significant increase of 68%[25] - Net cash flow from investment activities was $30,076,395.09, a turnaround from -$4,082,863.19 in the previous period[25] - Cash inflow from financing activities amounted to $13,010,000.00, compared to $8,222,600.00 in the last period, reflecting a growth of 58.5%[25] - Net cash flow from financing activities improved to $3,750,295.69 from -$23,377,116.80 in the previous period[25] - The ending cash and cash equivalents balance was $196,985,492.35, up from $112,793,039.47, indicating a strong liquidity position[25] - Cash received from the recovery of investments was $205,000,000.00, significantly higher than $120,000,471.85 in the previous period[24] - Total cash outflow from investment activities was $177,910,768.60, compared to $127,909,223.24 previously, reflecting increased investment efforts[25] Assets and Liabilities - The total assets at the end of the reporting period increased by 1.97% to ¥1,590,491,570.21 from ¥1,559,730,388.14 at the end of the previous year[4] - Total liabilities decreased to ¥568,174,417.08 from ¥584,430,625.34, a reduction of 2.8%[20] - The company's total equity attributable to shareholders rose by 5.25% to ¥952,505,623.84 from ¥905,009,796.36 at the end of the previous year[4] - The company's total equity rose to ¥1,022,317,153.13, compared to ¥975,299,762.80, marking an increase of 4.8%[20] Investments and Income - The company reported a 30.95% decrease in investment income to ¥2,586,300.00 compared to the previous year[9] - Investment income decreased to ¥2,586,319.40 from ¥3,745,773.20, a decline of 30.9%[22] - The company reported a fair value change loss of ¥526,013.84, contrasting with a gain of ¥2,670,735.94 in the previous period[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 15,829[12] - The largest shareholder, Yin Zhenglong, holds 26.90% of the shares, totaling 63,057,454 shares[12] - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. is the second-largest shareholder with a 10.16% stake, amounting to 23,819,959 shares[12] - The company has a total of 47,293,090 shares under lock-up due to executive restrictions[15] - The company repurchased 1,825,500 shares by the end of Q3 2024[13] - There are no changes in the top 10 shareholders participating in margin financing and securities lending[13] Inventory and Receivables - Accounts receivable increased by 49.36% to ¥158,714,100.00, primarily due to increased sales[8] - Accounts receivable increased to 158,714,089.03 RMB from 106,265,735.78 RMB, reflecting a growth of approximately 49.3%[18] - Inventory decreased to 81,234,134.67 RMB from 88,758,572.74 RMB, indicating a decline of about 8.6%[18] - The total current assets at the end of the period are 1,055,154,894.31 RMB, compared to 1,021,531,868.21 RMB at the beginning of the period, showing an increase of approximately 3.3%[18] Operating Costs - Total operating costs amounted to ¥200,329,332.30, up from ¥189,620,354.92, reflecting a rise of 5.9%[21] - Research and development expenses for the current period were ¥12,333,757.33, an increase of 4.7% from ¥11,783,747.62[21]

Financial Performance - The company's operating revenue for 2024 reached ¥882,573,320.58, representing a 5.16% increase compared to ¥839,259,534.36 in 2023[16]. - Net profit attributable to shareholders decreased by 26.07% to ¥119,424,741.26 in 2024 from ¥161,535,015.82 in 2023[16]. - The basic earnings per share fell by 26.09% to ¥0.51 in 2024, down from ¥0.69 in 2023[16]. - The total assets at the end of 2024 were ¥1,559,730,388.14, a 1.10% increase from ¥1,542,710,563.50 at the end of 2023[16]. - The company reported a net cash flow from operating activities of ¥118,332,669.23 in 2024, a decrease of 10.56% from ¥132,298,332.70 in 2023[16]. - The weighted average return on equity decreased to 13.67% in 2024 from 20.53% in 2023, a decline of 6.86%[16]. - The company has seen a decline in net profit after deducting non-recurring gains and losses, with a decrease of 26.45% to ¥101,157,550.11 in 2024 from ¥137,540,602.85 in 2023[16]. - The company reported a negative net profit in the fourth quarter of 2024, amounting to -¥3,001,117.77, indicating challenges in maintaining profitability[18]. Dividend Policy - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares (including tax) to all shareholders based on the total share capital as of the dividend record date, excluding 1.8255 million shares in the repurchase account[4]. - The company has not issued any bonus shares during the profit distribution plan, indicating a focus on cash dividends instead[4]. - The 2023 profit distribution plan was approved, with a cash dividend of 2.5 RMB per 10 shares, totaling 58.1537 million RMB distributed[147]. - For the 2024 profit distribution plan, a cash dividend of 3.0 RMB per 10 shares is proposed, with a total cash dividend amounting to approximately 69.79 million RMB[150]. Industry Position and Market Trends - The company is positioned in the pharmaceutical manufacturing industry, focusing on the pharmaceutical excipients sector, which is experiencing significant transformation and development[25]. - The government has increased support for the biopharmaceutical industry, emphasizing the development of innovative drugs and medical devices, which is expected to enhance market opportunities[26]. - The domestic pharmaceutical manufacturing industry achieved a revenue of CNY 25,298.5 billion in 2024, remaining flat year-on-year, which is below the overall industrial growth rate of +2.1%[27]. - The pharmaceutical manufacturing industry saw a profit of CNY 3,420.7 billion in 2024, representing a year-on-year decline of 1.1%[27]. - The market for pharmaceutical excipients is expected to grow significantly, driven by policies encouraging the development of high-end excipients and new adjuvants for vaccines[27]. Product Development and Innovation - The company has developed 50 products that have obtained drug excipient registration numbers from the CDE, indicating a strong product pipeline[30]. - The company focuses on optimizing product quality and expanding its product line, with a commitment to innovation based on market demand[30]. - The company has accelerated the research and industrialization of new fields such as injectable excipients and premix excipients[36]. - The company aims to complete 3-4 new product CDE registrations and increase R&D investment to meet market demand and improve product performance[96]. Research and Development - The company has invested in a new pharmaceutical excipient production base to expand capacity and strengthen its leading position in the industry[43]. - The R&D budget has been increased by 25% to support the development of innovative technologies and products[130]. - The number of R&D personnel increased by 8.13% to 173 in 2024, compared to 160 in 2023[61]. - Research and development expenses for 2024 were ¥40,952,648.76, a decrease of 2.38% compared to ¥41,952,772.69 in 2023[60]. Corporate Governance - The company has a complete and effective internal control system that spans all levels and aspects of its operations, continuously improving governance standards[112]. - The board of directors consists of 7 members, including 3 independent directors, which exceeds one-third of the total number of directors, complying with legal and regulatory requirements[109]. - The company maintains complete independence in business, personnel, assets, institutions, and finance from its controlling shareholder, ensuring no reliance on or unfair transactions with the controlling shareholder[113]. - The company has established a transparent investor relations management system, ensuring timely and accurate information disclosure to all shareholders[111]. Environmental Responsibility - The company holds valid pollution discharge permits from the Huainan Ecological Environment Bureau, expiring on May 12, 2028, and May 28, 2028[158]. - The company reported a total hazardous waste discharge of 2.58 tons, with no exceedances of discharge standards[159]. - The company has implemented strict environmental protection measures in accordance with relevant regulations and standards[158]. - The company has invested over 6 million yuan in environmental protection facilities and operations during the reporting period[164]. Risk Management - The company has outlined potential risks in its future development outlook, urging investors to pay attention to these risks[4]. - The company faces risks from fluctuations in raw material prices, particularly for key ingredients like wood pulp and refined cotton, which could impact profit margins if costs cannot be passed on to customers[97]. - The company emphasizes quality control throughout the production process to mitigate risks associated with operational errors and raw material quality[99]. Market Strategy - The marketing strategy will focus on "innovation industry, create market," expanding overseas markets and enhancing product recognition and market influence[93]. - The company is actively pursuing opportunities in the health food and plant capsule markets, as well as innovations in traditional Chinese medicine[93]. - The company plans to enhance its market presence and enhance product offerings through new technology development and strategic acquisitions[122]. Employee Management - The total number of employees at the end of the reporting period is 1,065, with 855 from the parent company and 209 from major subsidiaries[143]. - Annual training plans are developed by each department based on needs assessment and past training feedback, approved by the human resources department[146]. - The company maintains a salary policy that aligns with job value and differentiates based on technical and professional capabilities[145]. Shareholder Engagement - The annual shareholders' meeting had a participation rate of 43.24% on May 16, 2024[117]. - The first interim shareholders' meeting in 2024 had a participation rate of 31.56% on August 1, 2024[117]. - The second interim shareholders' meeting in 2024 had a participation rate of 28.16% on August 19, 2024[118]. - The third interim shareholders' meeting in 2024 had a participation rate of 28.85% on November 8, 2024[118].

山河药辅（300452）公告，2024年实现营业总收入8.83亿元，同比上升5.16%；归属于上市公司股东的 净利润1.19亿元，同比下降26.07%；扣除非经常性损益后的归属于上市公司股东的净利润1.01亿元，同 比下降26.45%。公司拟向全体股东每10股派发现金红利3元(含税)，送红股0股(含税)，以资本公积金向 全体股东每10股转增0股。 ...

山河药辅（300452）公告，2025年第一季度营收为2.48亿元，同比增长4.28%；净利润为4717.69万元， 同比下降5.30%。 ...

"聪明钱"流向曝光！暗盘资金破解主力操盘密码>> 化学制药板块短线拉升，罗欣药业（002793）、立方制药（003020）涨停,山河药辅（300452）涨超 10%，美诺华（603538）、森萱医药、天宇股份（300702）、昂利康（002940）、海翔药业（002099） 等跟涨。 ...

安徽山河药用辅料股份有限公司 简式权益变动报告书 上市公司名称：安徽山河药用辅料股份有限公司 股票上市地点：深圳证券交易所 股票简称：山河药辅 股票代码：300452 信息披露义务人名称：上海复星医药产业发展有限公司 住所：浦东新区康桥镇康士路25号350室（康桥） 通讯地址：上海市宜山路1289号A楼 股份变动性质：股份减少 签署日期：2025年4月3日 1 信息披露义务人声明 本部分所述词语或简称于本报告书"释义"所述词语或简称具有相同含义。 一、信息披露义务人依据《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司收购管理办法》、《公开发行证券的公司信息披露内容与格式与准则第15号 ——权益变动报告书》及其他相关法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》、《公开发行证券 的公司信息披露内容与格式与准则第15号——权益变动报告书》的规定，本报告书已全 面披露了信息披露义务人在安徽山河药用辅料股份有限公司中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通过 ...

安徽山河药用辅料股份有限公司 关于 2025 年第一季度可转债转股情况的公告 证券代码：300452 证券简称：山河药辅 公告编号：2025-011 债券代码：123199 债券简称：山河转债 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、"山河转债"（债券代码：123199）的转股期限为 2023 年 12 月 18 日起至 2029 年 6 月 11 日；最新的转股价格为人民币 13.60 元/股； （一）可转换公司债券发行情况 根据中国证券监督管理委员会《关于同意安徽山河药用辅料股份 有限公司向不特定对象发行可转换公司债券注册的批复》（证监许可 〔2023〕268 号），公司于 2023 年 6 月 12 日向不特定对象发行可转 换公司债券（以下简称"可转债"）3,200,000 张，每张面值人民币 100 元，发行总额 32,000.00 万元。 （二）可转换公司债券上市情况 经深交所同意，公司 32,000.00 万元可转换公司债券已于 2023 年 7 月 7 日起在深交所挂牌交易，债券简称"山河转债"，债券代码 "123199"。 （三）可转 ...